These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8633021)

  • 1. Dominant-negative p53 mutations selected in yeast hit cancer hot spots.
    Brachmann RK; Vidal M; Boeke JD
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4091-5. PubMed ID: 8633021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
    Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
    Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UV-induced mutagenesis of human p53 in a vector replicated in Saccharomyces cerevisiae.
    Moshinsky DJ; Wogan GN
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2266-71. PubMed ID: 9122183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple p53 functional assay for screening cell lines, blood, and tumors.
    Flaman JM; Frebourg T; Moreau V; Charbonnier F; Martin C; Chappuis P; Sappino AP; Limacher IM; Bron L; Benhattar J
    Proc Natl Acad Sci U S A; 1995 Apr; 92(9):3963-7. PubMed ID: 7732013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations in bladder carcinoma cell lines.
    Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
    Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A significant decrease of the transcriptional activity of p53 mutants deriving from human functional adrenal tumors.
    Lin SR; Yang YC; Jung JH; Tsai JH
    DNA Cell Biol; 1996 Oct; 15(10):793-803. PubMed ID: 8892752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses.
    Tada M; Iggo RD; Waridel F; Nozaki M; Matsumoto R; Sawamura Y; Shinohe Y; Ikeda J; Abe H
    Mol Carcinog; 1997 Mar; 18(3):171-6. PubMed ID: 9115587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas.
    Oda H; Nakatsuru Y; Ishikawa T
    Cancer Res; 1995 Feb; 55(3):658-62. PubMed ID: 7834636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
    Sakuragi N; Hirai A; Tada M; Yamada H; Yamamoto R; Fujimoto S; Moriuchi T
    Gynecol Oncol; 2001 Dec; 83(3):485-90. PubMed ID: 11733960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codon 249 of the human TP53 tumor suppressor gene is no hot spot for aflatoxin B1 in a heterologous background.
    Sengstag C; Mörbe JL; Weibel B
    Mutat Res; 1999 Nov; 430(1):131-44. PubMed ID: 10592324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype.
    Levine AJ; Wu MC; Chang A; Silver A; Attiyeh EF; Lin J; Epstein CB
    Ann N Y Acad Sci; 1995 Sep; 768():111-28. PubMed ID: 8526340
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro aflatoxin B1-induced p53 mutations.
    Chan KT; Hsieh DP; Lung ML
    Cancer Lett; 2003 Sep; 199(1):1-7. PubMed ID: 12963117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of cell death-deficient p53 mutants in Saccharomyces cerevisiae.
    Yacoubi-Hadj Amor I; Smaoui K; Belguith H; Djemal L; Dardouri M; Mokdad-Gargouri R; Gargouri A
    Yeast; 2009 Aug; 26(8):441-50. PubMed ID: 19579214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles.
    Rand A; Glenn KS; Alvares CP; White MB; Thibodeau SM; Karnes WE
    Cancer Lett; 1996 Jan; 98(2):183-91. PubMed ID: 8556707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast.
    Flaman JM; Robert V; Lenglet S; Moreau V; Iggo R; Frebourg T
    Oncogene; 1998 Mar; 16(10):1369-72. PubMed ID: 9546439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 transdominance but no gain of function in mouse brain tumor model.
    Hegi ME; Klein MA; Rüedi D; Chène P; Hamou MF; Aguzzi A
    Cancer Res; 2000 Jun; 60(11):3019-24. PubMed ID: 10850451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.
    Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B
    Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation.
    Volkmann M; Hofmann WJ; Müller M; Räth U; Otto G; Zentgraf H; Galle PR
    Oncogene; 1994 Jan; 9(1):195-204. PubMed ID: 8302580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of p53 tumor suppressor in yeast.
    Smardová J; Smarda J; Koptíková J
    Differentiation; 2005 Jul; 73(6):261-77. PubMed ID: 16138827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.